.
White/Caucasian
Black/African American
Native American
Asian
Myocardial Infarction
Sepsis and chronic rejection
Malignancy
Pulmonary embolism
Bronchial anastomotic dehiscence
The number of HIPEC-CRS procedures performed as well as postoperative outcomes have remained consistent over timewith no improvement in postoperative outcomes.
Significant improvements in operative time, 30-day postoperative morbidity, length-of-stay and 30-day readmission have been observed over time following HIPEC-CRS.
While the number of HIPEC-CRS has increased over time, postoperative clinical outcomes have worsened over time.
The number of HIPEC-CRS procedures performed has decreased over time while postoperative clinical outcomes have remained consistent with no significant improvements.
Neuroendocrine carcinoma
Adenocarcinoma
Carcinoid tumor
Goblet cell tumor
Better in regions with the highest diagnostic rates
Better in regions with the lowest diagnostic rates
Better in regions with the lowest diagnostic rates
Poor in both regions
Adequate in both regions
Worse outcome
Same as Caucasian
Equivalent to Caucasian
Unknown
Superior
Mixed results in patients undergoing esophagogastrectomy for cancer.
No impact on IHE and LOS in patients undergoing esophagogastrectomy for cancer.
An impact on IHE but not LOS in patients undergoing esophagogastrectomy for cancer.
An impact on LOS, but not IHE in patients undergoing esophagogastrectomy for cancer.
An impact on IHE and LOS in patients undergoing esophagogastrectomy for cancer.
The presence of nodal disease is associated with IHEs and prolonged LOS.
The presence of nodal disease is associated with IHEs, but not prolonged LOS.
There was no association of lung cancer, IHE's and prolonged length of stay.
The results regarding IHEs and prolonged LOS were inconclusive.
The presence of nodal disease is associated with prolonged LOS, and not IHE's.
Patients with a normal postoperative CA19-9 level.
Patients with an elevated postoperative CA19-9 level.
The delivery of adjuvant therapy provides no survival benefit to patients with PC after the receipt of neoadjuvant therapy, regardless of postoperative CA19-9 level.
Systemic therapy has no role in the management of localized pancreatic cancer.
Increased deceased donor kidney transplantation rates
Increased graft survival
Increased overall survival
Increased wait time
Decreased volume of transplant cases
Improved outcomes for transplant cases
Increased volume of transplant cases for centers that use the STAR model
An increased marginal cost of transplant cases
1-3 days
Within the first 7 days
Within the first 14 days
Within the first 30 days
Size of burn only
Inhalation injury only
Race only
Gender only
A, B and D
Quiz Review Timeline +
Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.